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Abstract: Amyloidopathies cause neurodegeneration in a substantial portion of the elderly population. Improvements in 
long term health care have made elderly individuals a large and growing demographic group, marking these diseases as  
a major public health concern. Alzheimer’s Disease (AD) is the most studied form of neurodegenerative amyloidopathy. 
Although our understanding of AD is far from complete, several decades of research have advanced our knowledge to  
the point where it is conceivable that some form of disease modifying therapy may be available in the near future. These 
advances have been built on a strong mechanistic understanding of the disease from its underlying genetics, molecular 
biology and clinical pathology. Insights derived from the study of other neurodegenerative diseases, such as some forms 
of frontotemporal dementia, have been critical to this process. This knowledge has allowed researchers to construct animal 
models of the disease process that have paved the way towards the development of therapeutics. However, what was once 
thought to be a straightforward problem has evolved into a series of disappointing outcomes. Examination of pathways 
common to all neurodegenerative diseases, including the cellular mechanisms that clear misfolded proteins and their  
regulation, may be the best way to move forward. 
Keywords: Amyloid, amyloid- peptide, amyloid- precursor protein, neurodegeneration, protein misfolding, proteinopathies, 
Tau. 
INTRODUCTION 
With Each Passing Decade, We Are Getting Older 
  The elderly make up a greater proportion of our popula-
tion than ever before, and this proportion is increasing. 
Demographic trends will continue to push our collective age 
to higher levels for the foreseeable future [1]. Although this 
represents a triumph of modern medicine, it brings along 
with it a series of problems and challenges. One of the most 
serious issues that this “graying society” must confront is the 
burden of age-related disease. Disorders that strike late in 
life already consume a staggering amount of resources. Un-
less significant steps are taken at both national and interna-
tional levels, in both the public and private sector, current 
signs indicate that this will become a crippling public health 
crisis by mid-century [2]. 
  Neurodegenerative disease is a significant part of this 
problem. Although Alzheimer’s disease (AD) is the most 
common neurodegenerative disease (Fig. 1), and the best 
known and studied, it is only one of a much larger class of 
age-related protein misfolding diseases that affect the central 
nervous system. Although there is some overlap, each dis-
ease presents with its own set of clinically distinct features 
and, in general, this clinical phenotype reflects the underly-
ing neuropathology. The majority of these diseases, which 
we can refer to as neurodegenerative amyloidopathies, have 
an insidious onset, with preclinical pathology developing 
over many years, if not decades. Often, by the time an indi- 
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vidual or their loved ones is aware that a problem exists, 
massive neurological damage has already been sustained. 
Since it is near certain that this damage cannot easily be re-
paired in the elderly brain, early detection, intervention and 
prevention will likely represent the future keys to successful 
treatment. 
 
 
 
 
 
 
 
 
Fig. (1). Distribution of the Major Age-Related Neurodegenerative 
Diseases. There are several different brain diseases that contribute 
substantially to cognitive impairment in the elderly. The weighted 
contributions shown on this pie chart are approximate and represent 
data collected from five different U.S. studies [8, 108-111]. Some 
other diseases that adversely affect cognition (including hippocam-
pal sclerosis) affect many persons but are not discussed in this re-
view. There is variation between studies due to population differ-
ences (e.g., mean age) and methodology. Thus, we have simplified 
these data for illustration. Note that AD accounts for more than 
one-half of cognitive impairment among American aged persons. In 
the “oldest old” (85+), some impact from cerebrovascular pathol-
ogy is almost universal, and it is normal for the brains of individu-
als over the age of 80 to harbor more than one type of pathology. AD and Neurodegeneration  Current Neuropharmacology, 2011, Vol. 9, No. 4    675 
  Each disease has one or more proteins that most likely 
form the core of the pathogenic process. In AD, a key player 
is often thought to be the amyloid- (A) peptide [3], first 
isolated as the principle component of amyloid deposits in 
the brain and cerebrovasculature of AD cases and Down’s 
Syndrome (DS) patients [4-6]. The second form of proteina-
ceous deposit in the AD brain, the neurofibrillary tangle 
(NFT), is comprised of polymers of a hyperpohosphorylated 
form of the microtubule associated protein tau, and this may 
be the main downstream effector of neuronal death [7]. The 
amount of NFTs in the cerebral cortex found upon autopsy 
correlates strongly with antemortem cognitive decline in 
clinical-pathological studies from many centers [8]. The 
“neuritic plaque”, which includes both the extracellular A 
deposition and a surrounding penumbra of degenerating neu-
rites with pathologically-folded tau, are the most specific 
histopathological lesions of AD. At this time AD is defined 
by the presence of all three of these: numerous NFTs,   
numerous neuritic plaques, and cognitive impairment [9]. 
Tau itself features prominently in additional neurodegenera-
tive diseases, called tauopathies (a specific subgroup of the 
broader amyloidopathies [10]), in which it is believed to be a 
major factor in neurodegeneration. Tauopathies comprise 
frontotemporal dementia with Parkinsonism linked to   
chromosome 17 (FTDP17; see below), Pick’s disease,   
corticobasal degeneration, progressive supranuclear palsy, 
and others. Many types of human prion disease, such as   
variant Creutzfeldt-Jakob disease and Gerstmann-Straussler-
Scheinker disease, exhibit amyloid deposition [11]. Deposits 
of the protein synuclein are commonly found in Parkinson’s 
disease [12] and in Lewy body dementia [13]. It has been 
suggested that Parkinson’s disease, Lewy body dementia and 
AD are all part of an overlapping disease spectrum [14]. Not 
all of these diseases have been examined in equal detail. 
However, there is much we can learn about common mecha-
nisms involved in neurodegeneration from examining those 
diseases that have been extensively studied, such as AD, and 
this can lead to valuable insights into how these diseases 
might be treated. 
ALZHEIMER’S DISEASE, FRONTOTEMPORAL 
DEMENTIA AND THE AMYLOID CASCADE 
  AD is the best understood neurodegenerative disease, and 
the most studied protein misfolding disease. The prevailing 
hypothesis for how AD develops is deceptively simple (Fig. 
2). The A peptide is produced from the larger amyloid- 
precursor protein (APP) through two sequential enzymatic 
activities,  - and -secretase.  -Secretase activity (mostly 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Factors Affecting Amyloid Accumulation and AD Pathology. In a broad sense, AD is characterized by neuronal degeneration, 
plaques and tangles. Strong evidence implicates the amyloid- precursor protein (APP), the source of the amyloid- peptide (A), as the 
central player in the pathophysiology of the disease. Various factors (pathogenic mutations, genetic modifiers, diet and metabolism, and even 
the aging process itself) conspire so that the steady state levels of A are extremely high in the AD brain. This can occur because of higher 
APP expression, increased APP metabolism (more - and / or -secretase activity), decreased A catabolism, faulty clearance of A from the 
brain, or some combination of these processes. Elevated levels of A, particularly aggregation prone species such as A42, lead to an increase 
in the amount of higher order oligomeric forms of the peptide (made up of two or more A molecules). These intermediates exist, at least 
transiently, in a toxic soluble form which probably exists both inside and outside the cell. There is evidence that oligomeric A damages 
neurons, leads to neurofibrillary tangles and eventual cell death, and ultimately forms highly insoluble fibrils that eventually deposit as 
plaques in the brain parenchyma. Oligomeric A also likely has other deleterious effects on neuronal function, only some of which have been 
characterized to date. Although AD is the best studied amyloidopathy, similar mechanisms (acting on proteins other than APP) may lie at the 
heart of many other neurodegenerative diseases. It is possible that knowledge of the common mechanisms contributing to these disease proc-
esses may lead to therapeutic approaches that are at least partially effective against neurodegeneration in general. 676    Current Neuropharmacology, 2011, Vol. 9, No. 4  Niedowicz et al. 
attributed to the BACE1 protein in the brain [15]) is usually 
thought of as the rate limiting enzyme in A production. -
Secretase activity leaves a membrane bound C-terminal 
fragment which is then cleaved by -secretase. This final 
cleavage generates the secreted A peptide and a cytosolic 
fragment which may offer a clue to the actual function of 
APP [3, 16-18]. The majority of A is 40 amino acids long 
(A40), but a small proportion (<10%) is slightly longer 
(A42). Higher levels of A42, the more hydrophobic and 
fibrillogenic form of the peptide, fosters the assembly of A 
into progressively higher order structures, from dimers all 
the way up to the insoluble plaques that finally deposit in the 
brain [19]. Since the more soluble assembled forms of the 
peptide are directly toxic [20], as the total amount of A in-
creases, neurons and synapses start to suffer deleterious con-
sequences and, ultimately, degenerate [21]. It is the wide-
spread elimination of synapses and death of neurons that 
causes the crippling memory deficit that eventually leads to 
the inability to sustain normal daily function. This hypothe-
sis, usually called the amyloid cascade hypothesis, is backed 
by an enormous amount of circumstantial evidence from 
multiple avenues of biological research [3]. 
  Although the range of data is compelling, the strongest 
evidence for the amyloid cascade in AD is genetic. Autoso-
mal dominant mutations that cause familial AD are present 
in both APP and the presenilins (PS1 and PS2). Since PS1 or 
PS2 form the active site of -secretase, this places AD causal 
mutations within either the substrate from which A origi-
nates (APP) or within the final enzyme in the production 
pathway. Many mutations have now been identified (an up to 
date list is maintained at http://www.alzforum.org/res/com/ 
mut/). Mutations in the presenilins lead to a shift in the pro-
duction of A towards the more amyloidogenic form, gener-
ally seen as an increase in the ratio of A42:A40; although 
there is some debate on the issue, this phenomenon is usually 
thought to reflect a loss rather than a gain of function [22, 
23]. Disease causing mutations in APP are clustered either 
within the A region or in close proximity to the - or -
secretase cleavage sites. After two decades of study, the mat-
ter of the actual biological function of APP is still unresolved 
[24]. 
  Even though true familial AD is rare (<5% of all cases), 
the overall heritability of AD is estimated at ~60% or 
greater, based on a study of the Swedish twin registry com-
prising close to 12,000 pairs of individuals with and without 
AD [25]. This points to the existence of multiple genetic risk 
factors, or modifiers, in addition to the known causative mu-
tations. The best known of these is the apolipoprotein E 
(ApoE) gene on chromosome 19 [26, 27]. There are 3 com-
mon alleles of the ApoE gene: 2, 3 and 4. When com-
pared to noncarriers, individuals heterozygous or homozy-
gous for the 4 allele have ~3 or ~12 fold elevated risk (re-
spectively) for developing AD in their lifetime [28]. In re-
cent years, several other genetic risk factors, all considerably 
weaker than ApoE genotype, have been documented in ge-
nome wide association studies [29]. Two of the largest ge-
nome-wide association studies to date identified three genes 
– clusterin (also known as apolipoprotein J), phosphatidyli-
nositol-binding clathrin assembly protein (PICALM) and 
complement receptor 1 (CR1) – that each contribute a small 
amount to the total AD risk [30, 31]. This is a continually 
evolving field, and an up to date database of the available 
evidence for each gene is freely available online (http:// 
www.alzgene.org/TopResults.asp). Compared to the auto-
somal dominant mutations that cause familial AD, much less 
is known about how these genetic modifiers affect AD 
pathogenesis. One likely mechanism is that they influence 
the rate of A aggregation [27, 29], because the ApoE4 allele 
certainly correlates with increased A deposition in brain 
parenchyma and around blood vessels. 
  The remaining AD risk is attributable to nongenetic, or 
environmental, factors. A wide range of variables has been 
associated with altered incidence of AD. Aging is thought to 
be the strongest nongenetic risk factor for the disease [32]. 
There are multiple reasons why the general process of aging 
might drive the development of AD. The simplest of these is 
that the accumulation of amyloid pathology in the brain is a 
slow process that occurs over many years. Similarly, age-
related decreases in normal cellular processes, such as general 
protein turnover, may play a major role [33]. Other systemic 
variables probably affect risk of AD over these long periods of 
time. There is compelling evidence that lifestyle, pharmaceuti-
cal use and overall health play a role in the development of the 
disease, although these topics have also generated controversy. 
For example, use of cholesterol lowering agents such as some 
statins [34] and some non-steroidal anti-inflammatory drugs 
(NSAIDs) [35] has been shown to lower AD risk in some but 
not all studies. A connection exists between increased risk for 
AD and Type 2 diabetes mellitus (T2DM), a metabolic disease 
that is tightly linked to obesity [36], although this is also con-
troversial [37]. This remains an area of active research. In this 
vein, considerable recent attention has been given to determin-
ing the role of leptin, an adipocyte-derived peptide hormone 
that regulates transcription via  multiple signal transduction 
pathways [38]. Low serum leptin is strongly correlated with 
increased AD risk, as well as greater cognitive decline during 
AD progression [39, 40]. Mid-life obesity is a known risk   
factor for AD [41]; however, T2DM and obese patients   
are hyperleptinemic, and yet have elevated levels of A [36]. 
The key may lie in the fact that these individuals develop 
leptin resistance, and over time become insensitive to their 
high levels of circulating leptin [38]. In other words, leptin 
may act as a normal physiological brake on the amount of A 
in the brain, and in some individuals this braking mechanism 
fails. 
  The final amount of A that accumulates as amyloid de-
posits in the brain is determined by the interplay of several 
factors: how much peptide is produced (discussed briefly 
above), how efficiently it is degraded within the brain, and 
how much of it is transported out into the periphery. The 
enzymes neprilysin (NEP) and insulin degrading enzyme 
(IDE) account for most A degradation [42-46], and the ac-
tivity of both decrease in normal aging and in disease-
affected regions [47, 48]. Neprilysin activity may also de-
crease in the CSF in early stages of AD [49]. In spite of these 
catabolic processes, a significant amount of A is not   
degraded, and is instead transported across the blood brain 
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exchanged across the BBB via the low-density lipoprotein 
receptor-related protein (LRP) on the abluminal (brain) side 
[50], and the receptor for advanced glycation end products 
(RAGE) on the luminal (blood) side [51]. Whether or not A 
simply hijacks this bidirectional mechanism or if it has   
a specific physiological function is not known. It is possible 
to predict the amount of deposited amyloid in the brain if  
the net efflux of A is known [52], and inhibiting this 
mechanism leads to an increase in A accumulation [53]. 
This indicates that faulty exchange processes or, possibly, 
general vascular abnormalities could contribute significantly 
to the development of A pathology in the brain [54]. 
  There has been a persistent debate over the relative toxic-
ity of the A peptide. Over the past decade, the focus on tox-
icity has shifted away from largely insoluble amyloid depos-
its towards more soluble forms of the peptide, particularly 
soluble oligomeric forms of A. Oligomeric forms of A are 
orders of magnitude more cytotoxic than fibrillar A (what is 
typically deposited in plaques), and trigger a different set of 
toxic events [55]. The concentration of soluble oligomers in 
CSF or brain interstitial fluid is in the pM range [56], and 
there is some evidence that insoluble A deposits in the brain 
may serve as a reservoir for more soluble A species [57]. 
The longer, more hydrophobic forms of A oligomerize 
more readily than the shorter, more soluble forms [58]. There 
is a good correlation between the ratio of A42 / A40 and the 
age of onset in familial AD [59], and A deposition in vivo is 
driven almost entirely by A42, and not A40 [60]. Higher 
order, soluble oligomeric forms of A are both toxic to neu-
rons and cause deficits in long term potentiation [20, 61], 
and species as small as dimers inhibit electrophysiological 
measures of synaptic transmission [62, 63]. Although it is 
widely agreed that soluble oligomers are cytotoxic, the 
mechanism is not yet established. It is possible that oligomers 
interact directly with the membrane bilayer, or through one 
or more cellular receptors [64, 65]. Additionally, there is also 
evidence that A42 stimulates formation of neurofibrillary 
tangles, effectively linking the two major AD pathologies 
[66, 67]. Although A oligomers are by far the most studied, 
there is good evidence that similar processes may operate in 
other neurodegenerative amyloidopathies [20]. 
  The study of non-AD forms of age-related neurodegen-
eration have helped expand our understanding of the under-
lying mechanisms that many of these diseases share. Fronto-
temporal dementia, or frontotemporal lobar degeneration 
(FTLD), has proven to be very informative. Nearly all cases 
of FTLD fall into 3 categories, based on the most prominent 
misfolded protein detected in the pathologic aggregates: tau, 
TDP-43 (TAR DNA binding protein 43), and Fus (fused in 
sarcoma) [68]. FTLD-tau disorders (Fig. 3) have direct and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). AD and FTD Pathologies. Representative gross photographs (A-C) and photomicrographs (D-G) demonstrate features of Alz-
heimer’s disease (AD) and frontotemporal dementia (FTD). Gross photographs of coronal slices of human brain at the level of the lateral 
geniculate nucleus show that AD brains can have extreme atrophy of the hippocampal formation (red arrows in A,B). A slightly more ante-
rior slice from an FTD patient (C) depicts the atrophy in the region of the temporal pole (black arrowhead). Silver stains show both neuritic 
plaques (D) and neurofibrillary tangles (E) in AD. Immunohistochemistry is useful to stain disease-related antigens: A peptide at low  
magnification in AD neocortex (F), and modified tau protein (“Pick bodies”) in the dentate granule cells in Pick’s disease, a subtype of FTD 
(G). Scale bars for photomicrographs: 20 μm in D,E; 1 mm in F, and 50 μm in G. 678    Current Neuropharmacology, 2011, Vol. 9, No. 4  Niedowicz et al. 
obvious implications for AD. A key discovery in this area 
was the linkage of mutations in the MAPT gene (which en-
codes tau) on chromosome 17 to the development of a sub-
type of frontotemporal dementia, FTDP17 [69, 70]. Muta-
tions that cause FTDP17 affect tau in at least two ways [10]. 
First, mutations in the coding sequence may either affect the 
ability of tau to bind to and stabilize microtubules, or may 
affect its propensity towards aggregation. Second, noncoding 
mutations alter the ratio of splice variants, particularly lead-
ing to imbalance in the expressed microtubule binding do-
mains. A striking characteristic of FTDP17 is that in spite of 
the presence of extensive tau pathology, A deposits are not 
a feature of this disease. In contrast, genetic causes of AD 
(by definition) increase the amount of A deposition and the 
development of tangle pathology. Together, these two dis-
eases show that abnormalities in tau can lead directly to neu-
rodegeneration, and that neurodegeneration caused by tau 
pathology does not cause A to deposit in the brain (Fig. 4). 
The corollary of this is that A pathology in AD most likely 
occurs upstream of tau pathology. 
  Researchers have used knowledge of the genetic and mo-
lecular mechanisms involved in the development of AD and 
related diseases to generate a variety of animal models of 
neurodegeneration [71-73]. These models have largely been 
developed in mice, and have advanced to the point where 
some strains have pathology present at or shortly after birth 
[74]. Robust pathology requires the introduction of some 
combination of familial AD mutations into APP, PS1, or tau, 
with the addition of more mutations producing an accelera-
tion of pathology. Also, although there are exceptions [75, 
76], it is necessary to over express APP containing human 
sequence A at relatively high levels (using an ectopic pro-
moter) to drive the A deposition in mice. As a consequence, 
in many models, the A produced is present alongside a 
small amount of endogenous rodent A, which may have 
some affect on the development of pathology [77-79]. 
  Genetically modified mice have proven to be useful tools 
in the study of the disease process. For instance, transgenic 
mice expressing a form of tau mutated in FTDP17 (P301L) 
were used to convincingly show that A controls the rate of 
development of tangle pathology [80, 81], demonstrating 
experimentally that abnormal A may occur before abnormal 
tau in the amyloid cascade. Mouse models have also been 
used to study the near real-time deposition of amyloid in the 
brain [82]. Remarkably, a large number of potential thera-
peutic interventions have been shown to have some success 
in one or more mouse models [83-85]. It is possible that A 
deposited in the mouse brain may be more plastic than that 
deposited in the human brain. This phenomenon may be re-
lated to the much shorter mouse lifespan, leading to lower 
levels of in vivo modification [86]. Less preclinical work has 
been carried out in models that also develop tau pathology, 
although this situation will likely change in the future. The 
absence of significant, bona fide tangle pathology in earlier 
mouse models may be one factor that accounts for why these 
models have turned out to be poorly predictive of clinical 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Comparison of AD and Tauopathies. In inherited or familial AD (FAD), the disease is characterized by neuronal degeneration, 
plaques, and tangles. FAD is caused by increased APP expression (such as in Down’s syndrome or in rare families with an extra copy of the 
APP gene), mutations in APP, or mutations in the presenilin genes, which all lead to an increase in aggregation- prone A. In chromosome 
17- linked frontotemporal dementia with parkinsonism (FTDP17), the disease is characterized by neuronal degeneration and tangles, but  
no plaques. In FTDP17, mutations in tau – the major component of neurofibrillary tangles – leads to tau dysfunction and / or aggregation. 
Other genetic and environmental factors can also lead to tauopathies. The most straight-forward conclusion is that tangle formation as a  
consequence of abnormalities in tau causes neurodegeneration. Since plaques are not a pathologic feature of tauopathies, we can also   
conclude that tau-induced neurodegeneration does not cause the formation of plaques. Since tangles occur in FAD along with A pathology, 
a simple synthesis of what we know about both diseases indicates that A (in some form) causes both tangles and neurodegeneration. AD and Neurodegeneration  Current Neuropharmacology, 2011, Vol. 9, No. 4    679 
success (see below). For instance, tau pathology is capable of 
propagation within the brain and does not require the pres-
ence of A pathology [87, 88]. This spread of altered tau in 
the brain indicates that once the disease process is triggered, 
the simple removal of A may be insufficient because tau 
pathology proceeds relatively unaltered. Regardless, over the 
past decade, the development of AD therapeutics has been 
heavily reliant on mouse models, and effectiveness in these 
mice has become almost a necessity for proceeding to human 
clinical trials. 
TREATING ALZHEIMER’S DISEASE 
  Recently, Myriad Genetics ceased development of Taren-
flurbil (Flurizan
TM), a promising candidate treatment for 
early-stage Alzheimer’s disease. This was the largest phase 
III clinical trial for an AD drug in history, enrolling nearly 
1600 patients in North America alone [89]. With the failure 
of Alzhemed
TM (tramiprosate) by Neurochem (now Bellus 
Health), this was the second high profile clinical failure 
within a year [90]. Although showing early promise as an 
AD therapy, Pfizer also recently announced that Lipitor® 
was not useful in slowing cognitive decline [91]. Add to the 
record the other recent therapeutic disappointments of non-
steroidal anti-inflammatory drugs (the NSAIDs Celebrex® 
and naproxen) [92] and estrogen replacement [93], and the 
tally of failure grows uncomfortably long. This streak is 
troubling in a number of ways. Is it enough to simply say 
that our first generation of disease-modifying agents   
are weak, and are not being administered early enough in  
the course of the disease, or are there other problems to   
consider? 
  Development of new therapeutics, or even new uses for 
old drugs, is a challenge. The odds are long, and the process 
near prohibitively expensive (the phase III trial of Flurizan 
cost in excess of $100 million dollars). Since the amyloid 
cascade hypothesis is supported by far more evidence than 
any other option, it is still the logical foundation on which to 
base the development of therapies that attempt to slow, or 
even reverse, AD. Targets include both the enzymes that 
generate A ( - and -secretases), as well as the peptide   
itself. Because drug development of any kind is a long   
shot, researchers are simply placing a well-educated wager. 
Nevertheless, after the recent string of losses on what 
seemed like good bets, these high-profile clinical failures 
may indicate that changes may be needed in thinking about 
how to treat AD and other forms of neurodegenerative   
amyloidopathies. 
  All of the three recent high profile failures had decent 
evidence of efficacy in small early trials [94-96]. Is it really 
fair to say that these different approaches failed because they 
were on the weak side of the therapeutic spectrum? It is   
possible that the dosing schedules were insufficient, or   
the bioavailability was poor, or that any number of other 
pharmocodynamic variables were not optimal. Although 
there is likely some truth in all of these statements, they   
ignore potentially larger problems. For instance, all of these 
approaches showed significant promise in pre-clinical animal 
models, and the efficacy was not remarkably different. 
Transgenic mice over expressing mutant forms of APP have 
been the animal models of choice for screening potential AD 
therapeutics [72]. In most studies, a promising candidate 
treatment reduces the amount of A in the brain from   
25% - 75%, with the observed reduction depending on a 
number of factors (how it is measured, the age and strain of 
the mice, etc). This suggests that the relative efficacy of a 
given compound at removing A in mice is a poor predictor 
of success as a treatment for AD in the clinic. Second, by 
extension this indicates that the animal model of choice is 
not as useful as was once thought. 
  The statement that the existing mouse models of AD are 
inadequate is far from heretical. It is widely appreciated that 
current animal models (mouse and others) only recapitulate a 
small portion of the human disease. In contrast to humans, 
APP over expressing transgenic mice never develop robust 
neurofibrillar pathology, nor do they show a remarkable loss 
of neurons. These discrepancies have been clearly recog-
nized in the literature, but their importance is perhaps all too 
often largely discounted. The reasoning typically put forth 
for the utility of these models is based on the amyloid   
hypothesis: if A is at the top of the amyloid cascade, the 
first step in the pathway to neurodegeneration, any agent that 
can accelerate its removal in an animal model is a good   
candidate for clinical trial. Based upon these key assump-
tions, there are still major late stage clinical trials underway 
– most notably immunotherapy (Elan and Wyeth, and others) 
and -secretase inhibition (Eli Lilly) – and it is possible that 
one of these will succeed where others have failed. However, 
since pre-clinical models have not yet predicted clinical   
success, and since these models indicated that all of these 
approaches were approximately equipotent (including those 
in current clinical trials), there does not appear to be good 
reason for optimism. 
  Many researchers have long considered anti-A42  
immunotherapy as the most promising approach geared   
towards clearing A from the brain. Immunotherapy is one 
of two remaining major approaches in clinical development 
that is thought to have the most promise (there are many 
others, that are less well developed), and is perhaps the most 
widely studied therapeutic in the AD field. The mechanism 
through which immunotherapy acts is not well understood, 
although the balance of evidence suggests A clearance 
through mass action or a “peripheral sink” [97]. In practice, 
either passive or active immunization is capable of inducing 
a near complete block of amyloid deposition in the brains of 
multiple mouse models, if administration occurs at an early 
age. Although later immunization is less effective, it still has 
some potency [98]. Immunized mice also show some cognitive 
improvement [99]. Two recent studies have raised what 
could be considered prominent warning signs. First, active 
immunization in a different species, aged canines, did not 
improve cognitive function in spite of clearing large amounts 
of deposited amyloid [100]. Second, a follow-up study in a 
small number of patients formerly enrolled in a phase I active 
immunotherapy study (AN1742) indicated that clinical pro-
gression and endpoint were unaltered in spite of substantial 
amyloid clearance [101]. The current clinical trials of   
anti-A42 immunotherapy will show if these warning signs 
predicted the ultimate outcome, but it is reasonable to   
believe that they will fare no better than Flurizan, Alzhemed 
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follow-up of Flurizan or Alzhemed treated patients might 
show a similar reduction in amyloid deposition without 
measurable clinical benefit. 
  What if immunotherapy (and -secretase inhibition) fails? 
This does not mean, as some have suggested, that the amy-
loid cascade model of the disease is wrong. What it does 
mean is that other important aspects of the disease are likely 
being overlooked. At least in the case of immunized patients 
that have come to autopsy, tau pathology appears relatively 
unaltered [101]. Perhaps it will turn out to be impossible to 
predict the success of a given approach unless it can be con-
currently evaluated for efficacy against the downstream con-
sequences of the disease, NFTs and neuronal degeneration. 
This will require a refocusing of development efforts using 
models that possess amyloid deposition along with true con-
current tangle pathology and frank neurodegeneration, rather 
than the surrogate markers that are frequently used. It is also 
possible that the end points evaluated in model systems are 
incorrect. Too much emphasis may have been placed on the 
insoluble pool of deposited amyloid rather than on the more 
soluble, oligomeric material. As mentioned above, the fact 
that many approaches can clear similar amounts of amyloid 
from the mouse brain could indicate that mouse amyloid is 
significantly more labile than the human form. Finally, per-
haps more effort should be devoted towards developing 
models that are less reliant on the overexpression of mutant 
proteins. Although a complete return to the drawing board is 
unlikely, AD therapeutic development is clearly further away 
from where it once was, where it once seemed likely that a 
disease- modifying drug would soon be available. 
  There is no doubt that improving the ability of clinicians 
to detect AD at an early stage will help. It is possible that A 
acts as a triggering mechanism that initiates a cascade of tau 
pathology and neurodegeneration early in the disease process 
and, after the initial burst of amyloid pathology, neuro- 
degeneration advances whether or not A is present. Recent 
studies show that tau pathology can progress and propagate 
between cells, and it is possible that this mechanism might 
be at work in the human disease [87, 88]. This scenario is 
akin to a runaway train, in that once the initial momentum 
(A) is imparted to the process, it may be difficult or impos-
sible to halt if this factor is removed. In this situation, the 
only hope is intervention in the cascade at the earliest possible 
moment. Based on current conceptualizations of AD, this 
would likely represent a phase with no or minimal hints of 
incipient dementia, since even mild cognitive impairment 
usually presents with both amyloid and tangle pathology 
[102]. It is widely hoped that advances in amyloid imaging 
and the use of more refined biomarkers of the disease will be 
the key [103]. Unfortunately, the reliable diagnosis of AD at 
the presymptomatic stage will be a costly undertaking, and is 
unlikely to occur in the near future. This makes the prospects 
for amyloid lowering agents as an AD monotherapy uncertain, 
at least for the time being. 
  Combining an A lowering agent with a tau clearance 
strategy may be what is called for, but it is by no means the 
only possibility. Neurodegenerative amyloidopathies, since 
they all involve protein misfolding to some degree, will all 
share some pathologic features in common. A worthwhile 
treatment possibility might involve targeting one or more of 
these common pathways. This could have the added advan-
tage of being efficacious for the treatment of multiple   
diseases, most of which have too small a patient population 
to spur more traditional large scale drug development efforts. 
There are many common biological mechanisms that are 
perturbed in neurodegenerative disease. As just one example, 
the process of autophagy is triggered across a range of   
neurodegenerative diseases [104]. This is likely a protective 
response to clear large quantities of aggregated protein. In 
fact, activating autophagy can both extend lifespan [105] and 
reverse amyloid pathology in mice [106]. Activation of a 
general clearance mechanism coupled with the inhibition of 
processes that generate the specific amyloidogenic protein 
may evolve into a promising general treatment strategy for 
neurodegenerative disease [107]. 
CONCLUSION 
  Although much is now known about Alzheimer’s Disease 
and related neurodegenerative conditions, understanding is 
far from complete. After several high profile failures based 
almost entirely on the removal of A, it is unclear how many 
additional drug trials will move forward based solely on the 
assumption that clearing this peptide will be an effective 
means of treating the disease. This comes at a time when the 
number of individuals with AD is climbing and the human 
and economic costs are growing at a staggering rate.   
Although it could be argued that some recent therapeutic 
failures might work well as preventative agents if given ear-
lier, it is unlikely that there will be lengthy and expensive 
primary prevention trials for drugs that have already been 
branded as clinical disappointments. However, if a point is 
reached where the remaining major clinical trials also fail, 
AD therapeutics will be entering into unsettled scientific 
territory. Future progress will face a far greater challenge 
than simple model tweaking, one that will require a   
reconsideration of the most basic assumptions of the past   
two decades. 
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